APGE (Apogee Therapeutics) LT-Debt-to-Total-Asset: 0.00 (As of Mar. 2026)


APGE Apogee Therapeutics Inc APGE
12 GF Score
Price $132.73
! 3 Warning Signs
View Full Analysis

What is Apogee Therapeutics LT-Debt-to-Total-Asset?

Apogee Therapeutics APGE +0.03% 12 LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus rates APGE with a GF Score™ of 12/100. The stock has 3 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Apogee Therapeutics's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.00.

Apogee Therapeutics's long-term debt to total assets ratio declined from Mar. 2025 (0.01) to Mar. 2026 (0.00). It may suggest that Apogee Therapeutics is progressively becoming less dependent on debt to grow their business.

Apogee Therapeutics  (NAS:APGE) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Apogee Therapeutics LT-Debt-to-Total-Asset Related Terms

Apogee Therapeutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Apogee Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apogee Therapeutics LT-Debt-to-Total-Asset Chart

Apogee Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
0.00 0.00 0.01 0.01

Apogee Therapeutics Quarterly Data
Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.00
APGE
12GF Score
Apogee Therapeutics Inc APGE
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apogee Therapeutics LT-Debt-to-Total-Asset Calculation

Apogee Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=5.345/937.134
=

Apogee Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=4.909/1293.654
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Apogee Therapeutics (APGE) has a LT-Debt-to-Total-Asset of 0.00 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Apogee Therapeutics and its competitors.
Is Apogee Therapeutics' LT-Debt-to-Total-Asset too high?
Apogee Therapeutics' current LT-Debt-to-Total-Asset is 0.00. Overall, Apogee Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Apogee Therapeutics' LT-Debt-to-Total-Asset compare to NUVL and CORT?
Apogee Therapeutics' LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Apogee Therapeutics and its competitors. Apogee Therapeutics's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apogee Therapeutics stock overvalued right now?
Apogee Therapeutics (APGE) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Apogee Therapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Apogee Therapeutics (APGE), the current LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Apogee Therapeutics Business Description

Address 221 Crescent Street, Building 17, Suite 102b, Waltham, MA, USA, 02453
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
12GF Score

Get the complete analysis for APGE

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$132.73
Price